Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
2024

Re-exposure to Ipilimumab plus Nivolumab in Metastatic Merkel Cell Carcinoma

Sample size: 3 publication Evidence: low

Author Information

Author(s): Valerie Glutsch, Patrick Schummer, Matthias Goebeler, Anja Gesierich, Bastian Schilling

Primary Institution: University Hospital Würzburg

Hypothesis

Can re-exposure to ipilimumab plus nivolumab improve outcomes in metastatic Merkel cell carcinoma patients who have progressed after initial treatment?

Conclusion

Re-exposure to ipilimumab plus nivolumab resulted in a 67% response rate in metastatic Merkel cell carcinoma patients who had previously progressed after initial treatment.

Supporting Evidence

  • Two out of three patients showed primary resistance to avelumab with progressive disease.
  • One patient showed complete response to avelumab but progressed after 13.4 months.
  • All three patients received combined ICI with IPI/NIVO as subsequent therapy, resulting in an ORR of ∼ 67%.

Takeaway

Doctors looked at three patients with a type of skin cancer who got a second chance at treatment and found that two of them got better again.

Methodology

Clinical data of three metastatic MCC patients who were re-exposed to IPI/NIVO after progression were retrospectively evaluated.

Limitations

The study is limited by the very small number of patients and the retrospective nature of data collection.

Participant Demographics

Three male patients aged 57 to 72 years with metastatic Merkel cell carcinoma.

Digital Object Identifier (DOI)

10.3389/fimmu.2024.1495004

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication